# VRG Therapeutics Kft.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vrg-therapeutics-kft

- Industry: Biotechnology
- Headquarters: Budapest, Hungary
- Website: www.vrgtherapeutics.com
- Total disclosed funding: $5.5M
- Latest round: Series A (Aug 14, 2023)
- Investors on record: 2

## About

Based in Budapest, Hungary, and founded in 2021, VRG Therapeutics Kft, a.k.a. VRG Therapeutics operates as a biotechnology company that develops biopharmaceuticals for treating diseases like cancer using its proprietary miniprotein ISEP technology. In August 2023, VRG Therapeutics Kft. raised EUR 5 million in a Series A funding led by Széchenyi Capital Fund Management, with participation from Vascular Venture. As of August 2023, Zalan Peterfi is the CEO of the company.

The company’s product lines are KV1.3, CTXA, KV10.1, chemo-genetics, Combi-X, and more. VRG Therapeutics leverages its proprietary mini protein ISEP technology to tackle diseases through mechanisms that conventional biopharmaceutical approaches cannot achieve, enabling patients to treat central nervous system (CNS) diseases.

VRG Therapeutics plans to use its proceeds from August 2023 to advance its pre-clinical drug candidate portfolio to IND, enabling studies for treating medical conditions like migraine prophylaxis, central nervous system (CNS) disorders, autoimmune diseases, and glioblastoma multiforme (GBM).

## Funding rounds

- Series A, Aug 14, 2023, $5.5M — Széchenyi Capital Fund Management, Vascular Venture

## Investors

- Széchenyi Capital Fund Management (https://capitalatlas.ai/funds/szechenyi-capital-fund-management) — Series A
- Vascular Venture (https://capitalatlas.ai/funds/vascular-venture) — Series A